DR. LOUIS FERNAND FABRE, MD
Psychiatric at Lake St, Houston, TX

6534507, Mar 18, 2003

Nov 13, 2000

09/709741

Stephen J. Kramer - Houston TX
Louis F. Fabre - Houston TX
Edward H. Ruediger - Greefield Park, CA
Joseph P. Yevich - Southington CT

Fabre-Kramer Pharmaceuticals, Inc. - Houston TX

A61K 31506

51425214, 51425218

Bioactive gepirone metabolites, such as 3-OH gepirone (4,4,-dimethyl-3-hydroxy-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedione), and their pharmaceutically acceptable salts and hydrates, can be used to alleviate psychological disorders or the symptoms thereof. The use of these compounds provides advantages over other therapeutic azapirones as they possess superior bioavailability, faster onset of action, and more stable plasma levels when administered to a mammal.

2009028, Nov 12, 2009

May 7, 2009

12/437180

Stephen J. KRAMER - Houston TX, US
Louis F. Fabre - Houston TX, US

Fabre-Kramer Pharmaceuticals, Inc. - Houston TX

A61K 31/497

51425218

The present invention relates to a method for alleviation, prevention, and treatment of attention deficit disorder, sexual dysfunction, and related conditions by administering certain bioactive metabolites of the known anti-depressant compound gepirone. In a preferred embodiment, the compound is 4,4,-dimethyl-3-hydroxy-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedione (3-OH gepirone).

2008024, Oct 9, 2008

Jun 16, 2008

12/139851

Stephen J. KRAMER - Houston TX, US
Louis F. Fabre - Houston TX, US

Fabre Kramer Pharmaceutical, Inc. - Houston TX

A61K 31/437, A61K 9/12

424 43, 514300

The present invention provides a method for inducing sleep, by nasally administrating to a subject in need thereof a pharmaceutical composition containing zolpidem, a pharmaceutically acceptable salt thereof, or a combination thereof, and a pharmaceutically acceptable nasal carrier in liquid form.

2006009, May 11, 2006

Nov 5, 2004

10/981663

Stephen Kramer - Houston TX, US
Louis Fabre - Houston TX, US

Fabre-Kramer Pharmaceuticals, Inc. - Houston TX

A61K 31/506, A61K 9/14

424488000, 514252180

The present invention relates to high-dosage extended-release formulation of gepirone and methods of treating major depression by administering the same to a subject in need thereof. More specifically, the present invention relates to a high-dosage extended-release tablet form of gepirone. The present invention also relates to a method of treating depression in mammals by administering to a subject in need thereof an effective amount the high-dosage extended-release formulation of gepirone in accordance with the present invention.

2005009, May 5, 2005

Jun 25, 2004

10/875384

Stephen Kramer - Houston TX, US
Louis Fabre - Houston TX, US

Fabre Kramer Pharmaceuticals, Inc. - Houston TX

A61K031/506, A61K009/20

424464000, 514252190

A pharmaceutical composition is provided, which includes: at least one active ingredient selected from the group including adatanserin, a compound having formula I, a compound having formula II, abaperidone, pharmaceutically acceptable salt thereof, prodrug thereof, and a mixture thereof; at least one high or medium viscosity hydroxypropylmethylcellulose (HPMC); at least one high or medium viscosity hydroxyethylcellulose (HEC); wherein the HPMC and HEC are present in a HPMC/HEC weight ratio ranging from 1/0.5 to 1/1.5; wherein adatanserin, abaperidone, and the compounds having formulas (I) and (II) are defined herein.

2004024, Dec 2, 2004

Mar 17, 2004

10/801856

Stephen Kramer - Houston TX, US
Louis Fabre - Houston TX, US

Fabre Kramer Pharmaceutical, Inc. - Houston TX

A61L009/04, A61K031/4745

424/045000, 514/303000

One embodiment of the present invention provides a pharmaceutical composition for nasal administration, which includes zolpidem, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a combination thereof, and a pharmaceutically acceptable nasal carrier in liquid form. Another embodiment of the present invention provides a method for inducing sleep, which includes nasally administering to a subject in need thereof a pharmaceutical composition, which includes zolpidem, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a combination thereof, and a pharmaceutically acceptable nasal carrier in liquid form.

2009028, Nov 12, 2009

May 7, 2009

12/437220

Stephen J. KRAMER - Houston TX, US
Louis F. FABRE - Houston TX, US

Fabre-Kramer Pharmaceuticals, Inc. - Houston TX

A61K 31/506, A61P 3/04, A61P 25/28, A61P 25/22, A61P 25/32, A61P 25/30, A61P 15/00

51425219

The present invention relates to a method for alleviation, prevention, and treatment of anxiety, depression, and sexual dysfunction by administering certain indolylalkyl derivatives of pyrimidinylpiperazine or metabolites thereof. A preferred embodiment is of the following formula:

2004000, Jan 1, 2004

Jun 28, 2002

10/183527

Stephen Kramer - Houston TX, US
Louis Fabre - Houston TX, US

Fabre Kramer Pharmaceutical, Inc. - Houston TX

A61K031/506, A61K031/4747

514/252150, 514/278000

The present invention relates to a method for treatment of attention deficit disorder by administering certain 5-HTreceptor agonists